Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Provided By GlobeNewswire
Last update: May 14, 2025
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter and year ended March 31, 2025.
Read more at globenewswire.com
